Literature DB >> 12899543

Cementless Spotorno tapered titanium stems: excellent 10-15-year survival in 141 young patients.

Peter R Aldinger1, Marc Thomsen, Hans Mau, Volker Ewerbeck, Steffen J Breusch.   

Abstract

We evaluated the clinical and radiographic results of the first consecutive 154 implantations of a cementless, double-tapered straight femoral stem (cementless Spotorno (CLS), Sulzer Orthopedics) in 141 patients under the age of 55 (mean 47 (13-55)) years. After a mean follow-up of 12 (10-15) years, 11 patients (11 hips) had died and 7 (7 hips) could not be located. 5 patients (5 hips) underwent femoral revision-1 for infection, 1 for periprosthetic fracture and 3 for aseptic loosening of the stem. The overall survival rate of the stem was 97% at 12 years (95% confidence limits, 93%-100%), and survival with femoral revision for aseptic loosening as an end point 98 (95-100)%. The survival rate of the acetabular components was 78 (71-85)% after 12 years. The median Harris hip score at follow-up was 84 points. None of the patients had thigh pain. Radiolucent lines in Gruen regions 1 and 7 were present in 21 hips (17%). 2 hips had radiolucent lines in regions 2-6 on anteroposterior (AP) radiographs. No femoral osteolysis was detected. The mid- to long-term survival with this type of femoral component is excellent and compares favorably with cemented stems in this age group. However, the high rate of cup loosening and the low Harris hip scores are a concern in this subgroup of young patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12899543     DOI: 10.1080/00016470310014157

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  25 in total

1.  [Cementless stems of the hip. Current status].

Authors:  H Effenberger; M Imhof; U Witzel; S Rehart
Journal:  Orthopade       Date:  2005-05       Impact factor: 1.087

2.  The Adaptiva custom-made stem--our reasons for not using it anymore.

Authors:  Patrik Karl Reize; Nikolaus Wülker
Journal:  Int Orthop       Date:  2006-05-31       Impact factor: 3.075

Review 3.  [Results for endoprosthetic care in patients younger than 50 years].

Authors:  J Ziegler; M Amlang; M Bottesi; S Kirschner; W-C Witzleb; K-P Günther
Journal:  Orthopade       Date:  2007-04       Impact factor: 1.087

Review 4.  [Hip arthroscopy for femoroacetabular impingement].

Authors:  M Wettstein; M Dienst
Journal:  Orthopade       Date:  2006-01       Impact factor: 1.087

5.  Survival of the cementless Spotorno stem in the second decade.

Authors:  Peter R Aldinger; Alexander W Jung; Steffen J Breusch; Volker Ewerbeck; Dominik Parsch
Journal:  Clin Orthop Relat Res       Date:  2009-06-06       Impact factor: 4.176

6.  Second-generation extensively porous-coated THA stems at minimum 10-year followup.

Authors:  David W Hennessy; John J Callaghan; Steve S Liu
Journal:  Clin Orthop Relat Res       Date:  2009-04-14       Impact factor: 4.176

7.  Cementless Total Hip Arthroplasty With Metasul Bearings Provides Good Results in Active Young Patients: A Concise Followup.

Authors:  Christian P Delaunay; Sophie Putman; Benjamin Puliéro; Matthieu Bégin; Henri Migaud; François Bonnomet
Journal:  Clin Orthop Relat Res       Date:  2016-10       Impact factor: 4.176

8.  Large femoral bone loss after hip revision using the uncemented proximally porous-coated Bi-Metric prosthesis: 22 hips followed for a mean of 6 years.

Authors:  Per Y Adolphson; Mats O F Salemyr; Olof G Sköldenberg; Henrik S G Bodén
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

9.  Increased risk of revision of acetabular cups coated with hydroxyapatite.

Authors:  Stergios Lazarinis; Johan Kärrholm; Nils P Hailer
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

10.  Custom stems for femoral deformity in patients less than 40 years of age: 70 hips followed for an average of 14 years.

Authors:  Michael Akbar; Guenther Aldinger; Knut Krahmer; Thomas Bruckner; Peter R Aldinger
Journal:  Acta Orthop       Date:  2009-08       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.